Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Spondyloarthritis family · A closer look at PsA

Reading PsA studies: endpoints, comparisons and meaningful benefit

Learn to translate a headline into a question you can examine: who was studied, what improved, compared with what, by how much and for how long?

Olga Goodman, MD · Sources checked 27 September 2026

Chapter 20 of 21

The essentials

A response is a change from baseline; remission is a defined state. A statistically significant result needs an effect size, uncertainty and a clear description of the outcome before it becomes useful.

Read the question before the conclusion

Identify the population, treatment, comparator, endpoint and assessment time. Participants with several swollen joints and no previous biologic treatment may not represent someone with mainly enthesitis after several treatment failures.

Randomisation assigns treatment by chance; blinding reduces the influence of knowing the allocation. A placebo comparison asks a different question from a direct comparison with another effective medicine. Observational studies provide valuable routine-care information, but treatment groups may differ before treatment begins.

Decode the outcome

An endpoint is the outcome chosen for measurement. Look for the prespecified primary endpoint, then supporting secondary and exploratory analyses. A favourable exploratory finding is useful for generating a hypothesis; it does not replace a failed primary comparison.

Decode the outcome
TermHow to interpret it
ACR20 / ACR50 / ACR70At least 20%, 50% or 70% improvement in tender and swollen joint counts and at least three of five other core measures. This is a response threshold, not that percentage of patients cured. 12
PASI75 / PASI90 / PASI100Improvement of a skin severity-and-area index by 75%, 90% or 100%. PASI100 indicates complete clearance on that measure; it does not measure joint control. 14
MDAMinimal disease activity: at least five of seven criteria. Because two can remain unmet, inspect the individual domains as well. 13
DAPSAA peripheral-joint activity score combining joint counts, pain, patient global assessment and CRP. DAPSA ≤4 defines remission in this measure; skin, entheses and axial symptoms still need their own assessment. 20
RemissionA low-activity state defined by a named measure. Ask which definition and whether it was sustained; the word alone does not mean cure.
ACR50 + PASI100Both requirements must be met in the same participant at the specified time. Check who was eligible for the skin analysis. 14
Function and patient-reported impactLook for changes in everyday ability, pain, fatigue and quality of life, alongside inflammatory measures.
Structural progressionChange in imaging damage over time. A good symptom response does not by itself prove prevention of structural damage.

Read absolute numbers and uncertainty

Teaching example—not trial data: 60 of 100 people respond with A and 40 of 100 with the comparator at week 24. The absolute difference is 20 percentage points; the relative increase is 50%. Both describe the same numbers, but the absolute figures make the size easier to see.

A confidence interval shows the uncertainty around an estimate under the study's assumptions. A p value does not state the probability that the treatment works or that the null hypothesis is true. Clinical importance depends on the outcome, its size, durability, burden and harms.

What a head-to-head result actually supports

SPIRIT-H2H compared ixekizumab with adalimumab. Its primary outcome required ACR50 and PASI100 together at week 24. Superiority on that combined outcome does not mean superiority for every joint, skin, safety or daily-life outcome separately. 14

Do not rank medicines by response percentages taken from unrelated trials. Different populations, background therapy, follow-up and rules for missing data can change those percentages. A network meta-analysis makes indirect comparisons with additional assumptions; it is not a new direct trial.

Read harms and missing data with the benefits

Check how many people stopped treatment, why they stopped and how missing outcomes were handled. An analysis of completers can look better if people doing poorly have already left. The intention-to-treat approach preserves the original treatment groups, but missing-data assumptions still matter.

For adverse events, compare denominators and exposure time. A short trial cannot reliably exclude rare or delayed harms. Also check the protocol or registry, funding and conflicts of interest; these guide appraisal rather than automatically invalidating a result.

Dr Google: how to spot a miracle cure — Open demo · no registration →

Go deeper

Non-inferiority, subgroups and the denominator

A non-inferiority trial asks whether the new treatment is no worse than the comparator by more than a prespecified margin. Failure to find a significant difference in an ordinary superiority trial does not prove equivalence.

Subgroup claims need adequate numbers and a formal test of whether effects differ between groups. A significant result in one subgroup and a nonsignificant result in another do not by themselves establish a difference.

When an article says “70% responded,” ask: 70% of everyone randomised, those who completed treatment or a skin-eligible subgroup? Write the numerator, denominator, endpoint and time together.

Questions for your visit

  1. Does this study population resemble my situation?
  2. Which outcome improved, and how large was the absolute benefit?
  3. Did benefit persist, and what happened to people who stopped treatment?

When to seek urgent help

A painful red eye, light sensitivity or a sudden change in vision needs urgent assessment. A newly hot, swollen joint, especially with fever or feeling unwell, also needs prompt assessment.

Sources & evidence notes

Sources checked 27 September 2026

Dates identify the cited publications. Protocols, exploratory analyses and clinical results answer different questions. This is a selected reading route, not a complete evidence review.

  1. Chung et al. ACR20/50/70 response criteria and trial discrimination (2006).
  2. Coates et al. Defining minimal disease activity in PsA (2010).
  3. Mease et al. SPIRIT-H2H: 24-week randomized direct comparison (2019).
  4. Schoels et al. DAPSA: defining remission and treatment success (2016).

Educational information for patients and caregivers. This personal publication is not the clinic portal and does not provide individual diagnosis or treatment. Discuss medication changes with your own care team.

© 2026 Olga Goodman, MD · A RheumaView publication. Copying without attribution prohibited.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Medical researchPsoriasisPsoriatic arthritisSpondyloarthritis